These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma. Atanasova VS, Pourreyron C, Farshchian M, Lawler M, Brown CA, Watt SA, Wright S, Warkala M, Guttmann-Gruber C, Hofbauer JP, Fuentes I, Prisco M, Rashidghamat E, Has C, Salas-Alanis JC, Palisson F, Hovnanian A, McGrath JA, Mellerio JE, Bauer JW, South AP. Clin Cancer Res; 2019 Jun 01; 25(11):3384-3391. PubMed ID: 30846478 [Abstract] [Full Text] [Related]
12. Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC. Martins VL, Caley MP, Moore K, Szentpetery Z, Marsh ST, Murrell DF, Kim MH, Avari M, McGrath JA, Cerio R, Kivisaari A, Kähäri VM, Hodivala-Dilke K, Brennan CH, Chen M, Marshall JF, O'Toole EA. J Natl Cancer Inst; 2016 Jan 01; 108(1):. PubMed ID: 26476432 [Abstract] [Full Text] [Related]
16. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Dermatology; 2009 Jan 01; 219(1):80-3. PubMed ID: 19439919 [Abstract] [Full Text] [Related]